Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Breast Neoplasms, Neoplasms

Triple Negative Breast Neoplasms

Neoplasm Metastasis

Ovarian Neoplasms

Breast Neoplasms, Patient Compliance

Pancreatic Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplastic Cells, Circulating

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Neuroma, Acoustic, Neurofibromatosis 2

Neoplasm Metastasis

Breast Neoplasms

Brain Neoplasms, Ependymoma, Neuroectodermal Tumors, Primitive, Glioma, Subependymal

Breast Neoplasms, Breast Neoplasms, Male

HER2 Positive Breast Cancer

Advanced Cancer

Breast Neoplasms

Colorectal Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Breast Neoplasms, Male

Carcinoma, Ductal, Breast

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Gallbladder Neoplasms

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Metastatic Breast Cancer With Intracranial Metastases

Prostatic Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Clinical Trials

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

MOST plus

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

DETECT III

ROME

INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Antineoplastic Drugs in Elderly Patients

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer

GW

ICK

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Concentration and Activity of Lapatinib in Vestibular Schwannomas

TSAP

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Bevacizumab in Multiple Phase I Combinations

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

STELA

MetAction

HERACLES

PAMELA

EPHOS-B

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

Neo-All-In

Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NRR

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

PIKHER2